Cambrex Corp (CBM): Steven M Klosk , President & CEO of Cambrex Corp sold 16,430 shares on May 3, 2016. The Insider selling transaction was reported by the company on May 5, 2016 to the Securities and Exchange Commission. The shares were sold at $49.27 per share for a total value of $807,242.88 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 5, 2016, William B Korb (director) sold 8,000 shares at $49.09 per share price.On Mar 17, 2016, Steven M Klosk (President & CEO) sold 19,565 shares at $41.00 per share price.Also, On Mar 16, 2016, Louis J. Grabowsky (director) purchased 750 shares at $40.10 per share price.On Mar 11, 2016, Gregory Sargen (Executive Vice President & CFO) sold 26,697 shares at $41.37 per share price.
Shares of Cambrex Corporation (CBM) ended Wednesday, May 4, 2016 session in red amid volatile trading. The shares closed down -0.66 points or -1.34% at $48.69 with 3,45,642 shares getting traded. Post opening the session at $48.91, the shares hit an intraday low of $48.36 and an intraday high of $49.49 and the price vacillated in this range throughout the day. The company has a market cap of $1,557 M and the number of outstanding shares has been calculated to be 3,19,78,467 shares. The 52-week high of Cambrex Corporation is $55.6 and the 52-week low is $29.5.
Company has been under the radar of several Street Analysts.Cambrex Corporation is Reiterated by Singular Research to Buy while Lowering the Price Target of the company shares to $ 60 from a previous price target of $63 . The Rating was issued on Feb 11, 2016.
Cambrex Corporation (Cambrex) is a life sciences company that provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Company’s customers include generic drug companies and companies that discover and commercialize small molecule human therapeutics using organic chemistry. Its business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Company’s products include active pharmaceutical ingredients (APIs) pharmaceutical intermediates and to a lesser extent other fine chemicals. Cambrex has three operating segments which are manufacturing facilities that have been aggregated as one reportable segment.